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1. Introduction 
Glycosylation adorns more than one half of the proteins in eukaryotic cells [1,2]. This 
post-translational modification plays an indispensible role in many important biological 
events, especially on cell surface [1,3]. Alterations in carbohydrate structures are known 
to correlate with the changes in protein stability and clearance, as well as various 
physiological functions including cell-cell adhesion, inflammation, tumor metastasis, and 
infection of bacteria and viruses [4-8]. Although glycosylation is essential for the 
formation and progression of various diseases, study of this subject is hampered by lack 
of effective tools available to date, in addition to structural heterogeneity and complexity 
of carbohydrates. A number of techniques have been developed to analyze the binding 
interactions between carbohydrates and proteins [2,9]. For instances, lectin 
blotting/binding assay has become a routine method to determine the glycan-protein 
interactions [10], but the relatively low sensitivity and the necessity of multiple wash 
steps/time-consuming have restricted the sensitivity and application. Surface plasmon 
resonance is another highly sensitive method which monitors the interactions in real 
time and in a quantitative manner [11-16]. However, sometimes the sensitivity is 
relatively low toward the use of low molecular-weight carbohydrates, though the 
problem can be overcome by labeling sugars with heavy metal ions [17]. In addition, 
fluorescence polarization and two-photon fluorescence correlation have been applied to 
study lectin-glycan interactions [18-21]. The most applicable technique is carbohydrate 
microarrays which immobilize oligosaccharides to a solid supports are developed and 
widely used to measure the carbohydrate binding properties of proteins, cells, or viruses 
[22-25]. For example, a high-content glycan microarray is developed by a robotic 
microarray printing technology in which amine-functionalized glycans are coupled to 
the succinimide esters on glass slides [26,27]. These microarrays have also been subjected 
for profiling the carbohydrate binding specificities of lectins, antibodies, and intact 
viruses. 
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2. Carbohydrate microarray 
In our recent work, we have developed two novel carbohydrate microarrays: solution 
microarray [28] and membrane microarray [29]. Carbohydrate solution assay is a high-
throughput, homogenous and sensitive method to characterize protein-carbohydrate 
interactions and glycostructures by in-solution proximity binding with photosensitizers 
(Figure 1). The technology, also called AlphaScreenTM, is first described by Ullman et al., and 
has been used to study interactions between biomolecules [30-34]. In these assays, a light 
signal is generated when a donor bead and an acceptor bead are brought into proximity. 
This method usually provides good sensitivity with femto-mole detection under optimized 
conditions, relying on the binding affinity between analytes. All the procedures are carried 
out in 384-welled microtiter plates, thus qualifying the protocol as high-throughput. Two 
particles of 200 nm are involved in this technology including streptavidin-coated particles 
(donor beads) and protein A-conjugated particles (acceptor beads). Biotinylated 
polyacrylamide (biotin-PAA)-based glycans that are immobilized on donor beads can be 
recognized by lectins or antibodies, and connected with acceptor beads through specific 
antibodies (Figure 1). A number of carbohydrate binding proteins, including eleven lectins 
and seven antibodies, are profiled for their carbohydrate binding specificity to validate the 
efficacy of this developed technology. This assay is performed in homogeneous solutions 
and does not require extra wash steps, preventing the loss of weak bindings that often occur 
in the repeating washes of glycan microarray. However, antigen/ligand excess effect may 
happen in the homogeneous solution assay if the concentrations of carbohydrate epitopes, 
proteins, or antibodies are too high. One mg of biotin-PAA-sugar can be applied for fifty 
thousand assays because minimal amount of materials are needed in this microarray system 
(a range of nano-gram is required per well). Although the detection limit of biotin-PAA-
sugar is good (2 ng per well), the linear range is too narrow for quantitative application.  
 
Figure 1. In-solution proximity binding with photosensitizers which was developed to characterize the 
protein-carbohydrate interactions [28]. 
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Carbohydrate membrane microarray is fabricated by immobilization of the biotin-
conjugated PAA-based glycans on aldehyde-functionalized UltraBind via streptavidin. 
Streptavidin interacted strongly with biotin and formed covalent linkage with membranes 
after reductive amination, which prevented the loss of glycans from membrane during 
repeated wash steps. The use of PAA also avoided the nonspecific interactions that take 
place in other studies between some lectins and non-glycosylated proteins (e.g. HAS or 
BSA) [35]. The operation of this carbohydrate membrane microarray is similar to that of 
Western blotting and can be performed easily by anyone without prior intensive training. 
3. Applications 
3.1. Carbohydrate binding profiles of lectins and antibodies (solution 
microarray) 
Fifty-four biotinylated polyacrylamide backboned glycans (biotin-PAA-glycans) (Table 1) 
are collected in total to examine fifteen carbohydrate-binding proteins, including eight 
lectins (Con A, DBA, GS-I, PNA, SBA, UEA-1, WFA and WGA), and six antibodies (anti-
Lea, Leb, Lex, Ley, sialyl Lea and sialyl Lex). The resulting signals are indicated with bars as 
relative intensities (Figures 2 and 3). The natural carbohydrate ligands for these lectins are 
listed in Table 2. All of the lectins showed nearly the same carbohydrate binding 
preferences as those in literatures. For example, concanavalin A (Con A) bound 
preferentially to mannose (No. 3) and biantennary N-glycan (No. 53), and very weakly to 
3- and 6-sulfated galactosides (No. 19, 23 and 25). DBA, a GalNAc-binding lectin, 
recognized GalNAcα1-3Gal-containing epitopes (No. 11 and 39). ECA interacted with 
LacNAc disaccharide, Galβ1-4(6-sulfo)GlcNAc, and Galβ1-4(α1-2Fuc)GlcNAc (No. 17, 24, 
31 and 47), and weakly bound to Lec (Galβ1-3GlcNAc, No. 20). GS-I preferred interacting 
with Gal/GalNAc that contains α1-3 or 1-4 linkage (No. 11, 13, 14, 16, 40 and 42). MAA, in 
this study, recognized mainly to 3’-sulfated Galβ1-3GlcNAc, 3’-sulfated Galβ1-4GlcNAc 
and LacNAc and weakly to 3-sialylated galactosides (No. 26, 37 and 53). PNA interacted 
with Galβ1-3GalNAc (No. 15) and bound to some galactosides weakly (No. 12, 16, 20, 45 
and 46). SBA preferentially interacted with α-linked galactosides (No. 16 and 42) and N-
acetylgalactosaminoside (No. 11). SNA, a well-known α2-6 sialoside-binding lectin, 
interacted strongly to 6’-sialyl lactose and sialylated diantennary N-glycan (No. 36 and 
53). UEA-1 specifically bound with Fucα1-2Gal-containing glycans (No. 18, 31 and 49). 
Due to weak interaction with PAA, WFA is the only one lectin showing higher 
background signals than the others. It recognized nearly half of the glycans on the glycan 
library, such as GlcNAc- and NeuAcα2-3-Gal/NeuAcα2-6-Gal containing saccharides. 
WGA also bound to terminal Gal or GalNAc epitopes (GalNAcα1-3Gal, No. 11 and Galβ1-
4(6HSO3)GlcNAc, No. 24) according to some minor signals. Interestingly, WGA showed 
better interactions with chitotriose than with chitobiose and GlcNAc. In addition, the 
binding specificities of monoclonal anti-carbohydrate antibodies also revealed some 
interesting features. As shown in Figure 3, anti-Lea antibody bound tightly with Lex, but 
less with Leb and sialyl Lea. Anti-Leb antibody represented specificities for both Leb and 
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Lea, but less for Lex and sialyl Lex. Anti-Ley antibody not only binding to Ley, but also 
recognized lactose, Lex, sialyl Lex and H type 2 structures. We also compared the binding 
patterns of lectins with the results reported by Blixt and coworkers at CFG in which 264 
different glycans are studied by using the printed microarray (Ver. 2) 
(http://www.functionalglycomics.org/glycomics/publicdata/ primaryscreen.jsp). There are 
forty-seven glyco-epitopes are found to be identical in both analyses. Even the different 
principles and procedures of the two systems, the binding patterns of eight lectins are 
nearly the same, except for a few minor differences. For example, our characterized 
patterns of WFA and WGA show 90% similarity to the CFG data. Nevertheless, the 
interactions of SBA, WFA and WGA to β-GalNAc (No. 2) in the CFG’s printed microarray 
are not observed in our system. Both of our method and the printed microarray indicate 
that MAA preferentially binds to sulfated glycans [36]. Because of the observed 
consistency shown by the two very different methods, we conclude the protein-glycan 
binding interactions are not affected by the PAA linker, the assay procedure (washing vs. 
non-washing) and the interacting microenvironment (2D for printed microarray vs. 3D for 
our solution microarray). 
 
 
Table 1. List of biotin-PAA-glycans (fifty-two) used in glycan solution microarray [28]. 
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Figure 2. Carbohydrate binding specificities of eleven lectins characterized by glycan solution 
microarray [28]. 
 
 
Figure 3. Carbohydrate binding specificities of six antibodies characterized by glycan solution 
microarray [28]. 
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Table 2. Carbohydrate ligands of commercial available lectins. 
3.2. Binding patterns of seventeen lectins and four antibodies (membrane 
microarray) 
The principle and procedures of carbohydrate membrane microarray are showed in Figure 
4. The western blotting like procedures not only reduces the time and interference, but also 
increases the application of this platform. In order to look deep inside the carbohydrate 
binding preferences of proteins and microorganisms, the collections of biotin-PAA-glycans 
were to increased eighty-eight different structures (Table 3). The glycan binding specificities 
of sixteen lectins (six alkaline phosphatase (AP)-conjugated lectins, four FITC-conjugated 
lectins, six unconjugated lectins) and four Lewis blood-group antibodies are evaluated and 
showed in Figures 5 and 6. All the lectins recognized the glycans that are consistent with the 
literature. For instance, ECA preferentially interacted with LacNAc, lactose, GalNAc, and 
Gal terminal sugars; PNA specifically bound to the Galβ1-3GalNAc structure; SBA 
dominantly recognized α-linked GalNAc epitopes; 3-sulfate LacNAc is ligand for MAA [36]. 
Compare the patterns of unconjugated lectins with conjugated lectins (AP- or FITC-
attached) indicated that the glycan preferences of ECA and PNA are not interfered by 
conjugation. More binding signals are observed in the binding profiles of AP-conjugated 
MAA, SBA and WGA compared with unconjugated or FITC-attached ones. Additionally, 
the binding patterns of DBA, ECA, GS-I, MAA, SBA and VVA are highly consistent with 
those reported by Consortium for Functional Glycomics (CFG, printed microarray Ver. 2,). 
However, few inconsistencies are also observed in the study of MPA, PNA, UEA and WGA. 
Furthermore, the binding patterns of four Lewis blood group antibodies represented very 
high specificities (Figure 6). 
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Figure 4. Fabrication, principle, and procedures of carbohydrate membrane microarray [29]. 
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S-1 Blank-PAA-biotin S-46 Neu5Ac2-6Gal-PAA-biotin 
S-2 -GlcNAc-sp-biotin S-47 Neu5Gc2-6GalNAc-PAA-biotin
S-3 -Mannose-PAA-biotin S-48 Neu5Ac2-3GalNAc-PAA-biotin
S-4 -GlcNAc-PAA-biotin S-49 Blood Group A-tri-PAA-biotin
S-5 -GalNAc-PAA-biotin S-50 Blood Group B-tri-PAA-biotin
S-6 -L-Fuc-PAA-biotin S-51 H(type2)-PAA-biotin
S-7 -Neu5Ac-PAA-biotin S-52 Lea-PAA-biotin
S-8 
-Neu5Ac-OCH2C6H4-p-NHCOOCH2-PAA-
biotin 
S-53 Lex-PAA-biotin 
S-9 MDP(muramyl dipeptide)-PAA-biotin S-54 Led(H type1)-PAA-biotin
S-10 -Neu5Gc-PAA-biotin S-55 3'Sialyl-Lactose-PAA-biotin
S-11 -D-Gal-3-sulfate-PAA-biotin S-56 6'Sialyl-Lactose-PAA-biotin
S-12 -D-GlcNAc-6-sulfate-PAA-biotin S-57 3-HSO3-Lex-PAA-biotin
S-13 GalNAc1-3Gal-PAA-biotin S-58 3-HSO3-Lea-PAA-biotin
S-14 Gal1-3Gal-PAA-biotin S-59 Gal1-4Gal1-4Glc-PAA-biotin
S-15 Fuc1-2Gal-PAA-biotion S-60 Gal1-3Gal1-4Glc-PAA-biotin
S-16 Lec(Gal1-3GlcNAc)-PAA-biotin S-61 GlcNAc1-2Gal1-3GalNAc-PAA-biotin 
S-17 Gal1-4Glc-PAA-biotin (Lactose) S-62 Neu5Ac2-3Gal1-4GlcNAc-PAA-Biotin 
S-18 LacNAc-PAA-biotin S-63 3'Sialyl-Lec-PAA-biotin
S-19 Fuc1-3GlcNAc-PAA-biotin S-64 Gal1-3Gal1-4GlcNAc-PAA-biotin, sp=-
NHCOCH2NH- 
S-20 Fuc1-4GlcNAc-PAA-biotin S-65 GlcNAc1-3Gal1-3GalNAc-PAA-biotin 
S-21 GalNAc1-3GalNAc-PAA-biotin S-66 GlcNAc1-3Gal1-3GalNAc-PAA-biotin 
S-22 Gal1-3GalNAc-PAA-biotin S-67 Gal1-3(GlcNAc1-6)GalNAc-PAA-biotin 
S-23 Gal1-3GalNAc-PAA-biotin S-68 Blood type A (tri)-PAA-biotin, 
sp=(CH2)3NHCO(CH2)5NH- 
S-24 Gal1-3GalNAc-PAA-biotin S-69 Blood type B (tri)-PAA-biotin, 
sp=(CH2)3NHCO(CH2)5NH- 
S-25 Gal1-3Gal-PAA-biotin S-70 GlcNAcb1-3Gal1-4GlcNAc-PAA-biotin 
S-26 GlcNAc1-3Gal-PAA-biotin S-71 Neu5Ac2-3Gal1-3GalNAc-PAA-Biotin 
S-27 LacNAc-PAA-biotin S-72 GlcNAc1-3(GlcNAc1-6)GalNAc-PAA-biotin 
S-28 Glc1-4Glc-PAA-biotin S-73 Gal1-4Gal1-4GlcNAc-PAA-biotin
S-29 Gal1-3GalNAc-PAA-biotin, sp=-p-OC6H4- S-74 GlcNAc1-4GlcNAc1-4GlcNAc-PAA-biotin 
S-30 Gal1-2Gal-PAA-biotin S-75 Gal1-3(Neu5Ac2-6)GalNAc-PAA-biotin 
S-31 GlcNAc1-4GlcNAc-PAA-biotin S-76 Neu5Ac2-3(Neu5Ac2-6)GalNAc-PAA-biotin 
S-32 
GlcNAc1-4GlcNAc-PAA-biotin, sp=-
NHCOCH2NH-
S-77 Gal1-4GlcNAc1-3GalNAc-PAA-biotin 
S-33 Neu5Ac2-6GalNAc-PAA-biotin S-78 Leb-PAA-biotin
S-34 H(type 3)-PAA-biotin S-79 Ley-PAA-biotin
S-35 3-HSO3-Gal1-4GlcNAc-PAA-biotin S-80 Sialyl Lea-PAA-biotin
S-36 3-HSO3-Gal1-3GlcNAc-PAA-biotin S-81 Sialyl Lex-PAA-biotin
S-37 Gal1-6Glc-PAA-biotin (melibiose) S-82 GlcNAc1-3(GlcNAc1-6)Gal1-4Glc-PAA-biotin 
S-38 
Neu5Ac2-8Neu5Ac-sp**-PAA-biotin, 
(Neu5Ac)2 
S-83 Gal1-3(Fuc1-2)Gal1-4GlcNAc-PAA-biotin 
S-39 Gal1-2Gal-PAA-biotin S-84 Gal1-3GlcNAc1-3Gal1-4Glc-PAA-biotin 
S-40 6-HSO3-Gal1-4GlcNAc-PAA-biotin S-85 Gal1-4GlcNAc1-3Gal1-4Glc-PAA-biotin 
S-41 Neu5Ac2-3Gal-PAA-biotin S-86 (NeuAc2-8)5-6-PAA-biotin
S-42 Gal1-4(6-HSO3)GlcNAcb-PAA-biotin S-87 Gal1-4GlcNAc1-3(Gal1-4GlcNAc1-6)GalNAc-
PAA-biotin 
S-43 
3-HSO3-Gal1-3GalNAc-PAA-biotin 
(sulfate-TF) 
S-88 2-6 sialylated diantennary N-glycans-PAA-biotin 
S-44 GlcNAc1-3GalNAc-PAA-biotin S-89 GalNAc--Ser-PAA-biotin 
S-45 GlcNAc1-6GalNAc-PAA-biotin S-90 H2O
2-6 sialylated diantennary N-glycans :(NeuAc2-6Gal1-4GlcNAc1-2Man)21-3,6Man1-4GlcNAc1-4GlcNAc 
Table 3. List of biotin-PAA-glycans (eighty-eight) used in carbohydrate membrane microarray [29]. 
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Figure 5. Carbohydrate binding specificities of sixteen lectins (six alkaline phosphatase-conjugated 
lectins, four FITC-conjugated lectins, and six unconjugated lectins) characterized by carbohydrate 
membrane microarray [29]. 
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Figure 6. Carbohydrate binding specificities of four antibodies characterized by carbohydrate 
membrane microarray [29]. 
3.3. Surveillance of seasonal and pandemic H1N1 influenza A viruses 
(membrane microarray) 
Several methods are applied for exploring the carbohydrate-binding preference of influenza 
viruses or recombinant HA, including cell-based assays [37-39], immobilization of virus [40-
46] and glycan microarray technology [47-49]. In our study, 30 biotin-PAA-glycans (Table 4, 
most of them were sulfated and sialylated) were selected and fabricated on membrane and 
applied for the carbohydrate ligand surveillance of influenza clinical isolates. We subjected 
this influenza membrane microarray to characterize the glycan-binding features of five 
seasonal influenza A (H1N1) and seven A(H1N1)pdm09 clinical isolates. The binding 
patterns of all studied viruses are successfully profiled, with each virus exhibiting different 
and clear patterns, thereby enabling characterization (Figure 7, Lane 1 to 12). The majority 
of the seasonal H1N1 viruses bound strongly to 6'-sialyl lactose and sialyl biantennary N-
glycan (Figure 7, Lane 1 to 5). A/Taiwan/1156/2006, A/Taiwan/510/2008, and 
A/Taiwan/289/2009 isolates interacted with the two glycans, and with numerous α2-3 
sialylated structures, including 3'-sialyl lactose, NeuAcα2-3(NeuAcα2-6)GalNAc, sialyl Lea, 
and sialyl Lex. In addition, A/Taiwan/1156/2006 isolate also recognized NeuAc (linked to p-
aniline), NeuGc, some of the sulfated glycans (3'-sulfated Lea, 3'-sulfated Lex, 6-sulfate 
LacNAc and 6'-sulfate LacNAc), NeuAcα2-6GalNAc, and a NeuAcα2-8 dimer. Contrary to 
seasonal H1N1 isolated in 2009, pandemic (H1N1) isolated in 2009 accepted more substrates 
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(Figure 7, Lane 6 to 9). California/07/2009 and A/Taiwan/2024/2009 bound with 6-sulfate 
GlcNAc, 3'-sulfated Lea, 3'-sulfated Lex, all of the 2-3 sialylated glycans with the exception of 
NeuAcα2-3GalNAc, 6'-sialyl lactose, sialyl biantennary N-glycan, and α2-8 oligomers. 
A/Taiwan/942/2009 favored four sulfated glycans (3-sulafe Gal, 6-sulfate GlcNAc, 3'-sulfated 
Lea and 3'-sulfated Lex), most of the 2-3 sialylated glycans (except NeuAcα2-3Gal and 
NeuAcα2-3GalNAc) and three 2-6 sialylated glycans (NeuAcα2-6Gal, 6'-sialyl lactose and 
sialyl biantennary N-glycan). A/Taiwan/987/2009 recognized most of the PAA-sugar 
substrates tested, with the exception of the PAA backbone, muramyl dipeptide, αNeuAc, 3-
sulafe Galβ1-4GlcNAc, 3-sulafe Galβ1-3GlcNAc and Galβ1-3(NeuAcα2-6)GalNAc. In 
addition, we found that pandemic (H1N1) viruses isolated in 2009 represented broader 
substrate specificities than the pandemic viruses isolated in 2010, especially to sulfated 
sugars. A/Taiwan/395/2010 and A/Taiwan/1477/2010 recognized NeuAcα2-3Gal, 3'sialyl 
lactose, NeuAcα2-3Galβ1-3GlcNAc, sialyl-Lea, NeuAcα2-6GalNAc, NeuAcα2-6Gal, 6'-sialyl 
lactose, and sialyl biantennary N-glycan (Figure 7, Lane 11 to 12). A/Taiwan/257/2010 
accepted only six glycans including NeuAc (linked to p-aniline), 3'sialyl lactose, NeuAcα2-
6GalNAc, NeuAcα2-6Gal, 6'-sialyl lactose, and sialyl biantennary N-glycan (Figure 7, Lane 9). 
 
I-1 Blank-PAA-biotin I-17 Neu5Gc2-6GalNAc-PAA-biotin 
I-2 -Neu5Ac-PAA-biotin I-18 Neu5Ac2-3GalNAc-PAA-biotin 
I-3 
-Neu5Ac-OCH2C6H4-p-NHCOOCH2-
PAA-biotin 
I-19 3'Sialyl-Lactose-PAA-biotin 
I-4 MDP(muramyl dipeptide)-PAA-biotin I-20 6'Sialyl-Lactose-PAA-biotin 
I-5 -Neu5Gc-PAA-biotin I-21 3-HSO3-Lex-PAA-biotin 
I-6 -D-Gal-3-sulfate-PAA-biotin I-22 3-HSO3-Lea-PAA-biotin 
I-7 -D-GlcNAc-6-sulfate-PAA-biotin I-23 Neu5Ac2-3Gal1-4GlcNAc-PAA-
Biotin 
I-8 Neu5Ac2-6GalNAc-PAA-biotin I-24 3'Sialyl-Lec-PAA-biotin 
I-9 3-HSO3-Gal1-4GlcNAc-PAA-biotin I-25 Neu5Ac2-3Gal1-3GalNAc-PAA-
Biotin 
I-10 3-HSO3-Gal1-3GlcNAc-PAA-biotin I-26 Gal1-3(Neu5Ac2-6)GalNAc-PAA-
biotin 
I-11 
Neu5Ac2-8Neu5Ac-sp**-PAA-
biotin, (Neu5Ac)2 
I-27 
Neu5Ac2-3(Neu5Ac2-6)GalNAc-
PAA-biotin 
I-12 6-HSO3-Gal1-4GlcNAc-PAA-biotin I-28 Sialyl Lea-PAA-biotin 
I-13 Neu5Ac2-3Gal-PAA-biotin I-29 Sialyl Lex-PAA-biotin 
I-14 Gal1-4(6-HSO3)GlcNAcb-PAA-biotin I-30 (NeuAc2-8)5-6-PAA-biotin 
I-15 
3-HSO3-Gal1-3GalNAc-PAA-biotin 
(sulfate-TF) 
I-31 
2-6 sialylated diantennary N-glycans 
-PAA-biotin 
I-16 Neu5Ac2-6Gal-PAA-biotin I-32 H2O 
2-6 sialylated diantennary N-glycans :(NeuAc2-6Gal1-4GlcNAc1-2Man)21-3,6Man1-4GlcNAc1-4GlcNAc 
Table 4. List of biotin-PAA-glycans (thirty) fabricated on carbohydrate membrane microarray for 
carbohydrate binding surveillance of influenza clinical isolates [29] [50]. 
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Figure 7. Carbohydrate binding profiles of twelve influenza A clinical isolates characterized by 
carbohydrate membrane microarray [50]. 
3.4. Surveillance of influenza B clinical isolates (membrane microarray) 
The influenza carbohydrate membrane microarray is subsequently subjected for the 
surveillance of twelve influenza B (IB) clinical isolates [50]. All of the viruses are collected 
in the Clinical Virology Laboratory of National Cheng Kung University Hospital between 
2001 and 2004. The clinical isolates are amplified in MDCK cells and purified by a sucrose 
gradient. The binding patterns of the influenza B viruses are investigated and are all 
found to exhibit clear binding profiles (Figure 8). Three common glycans, including α-
Neu5Ac (p-anilinyl linked), 6'sialyl-lactose, and α2-6 sialylated biantennary N-glycans are 
bound by all of the influenza B viruses. Furthermore, some additional bindings are also 
observed. For instance, B/Taiwan/314/2001 and B/Taiwan/1729/2002 also recognized 
sulfated sugars (3-sulafe Gal, 6-sulfate GlcNAc, Galβ1-4(6-HSO3)GlcNAc, and 3'-sulfated 
Lea) and two α2-6 sialosides (NeuAcα2-6GalNAc and NeuAcα2-6Gal). B/Taiwan/288/2002 
and B/Taiwan/1902/2004 portrayed minor interactions with α2-3 (3'-sialyl lactose, 
NeuAcα2-3Galβ1-4GlcNAc, 3'-sialyl Lec and sialyl Lex) and α2-6 sialylated sugars 
(NeuAcα2-6GalNAc and NeuAcα2-6Gal). Although the signal is relatively low, 
B/Taiwan/872/2004 and B/Taiwan/913/2004 also interacted with sulfated sugars. 
Surprisingly, seven viruses showed weak bindings to α2-8 linked sialic acids, including 
B/Taiwan/314/2001, B/Taiwan/174/2002, B/Taiwan/288/2002, B/Taiwan/1729/2002, 
B/Taiwan/872/2004, and B/Taiwan/913/2004. 
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Figure 8. Carbohydrate binding profiles of sixteen influenza B clinical isolates characterized by 
carbohydrate membrane microarray [50]. 
The DNA sequences of hemagglutinin of the twelve influenza B clinical isolates were 
analyzed, translated into sequences of amino acids, and aligned with B/HongKong/8/73, 
Victoria (B/Victoria/02/87), and Yamagata (B/Yamagata/16/88) lineages using online 
software EBI ClustalW2. Surprisingly, the twelve influenza B clinical isolates could all be 
categorized into two groups depending on protein sequence alignment. Group 1 
contained eight clinical isolates (B/Taiwan/314/2001, B/Taiwan/174/2002, 
B/Taiwan/288/2002, B/Taiwan/1729/2002, B/Taiwan/1994/2002, B/Taiwan/872/2004, 
B/Taiwan/913/2004 and B/Taiwan/1902/2004, Figure 8, Table 5) and Group 2 contained 
four viruses (B/Taiwan/262/2001, B/Taiwan/925/2001, B/Taiwan/966/2001, 
B/Taiwan/2284/2001). We found that all of the viruses in group 2 were isolated in 2001. In 
addition, there were twelve amino acid differences between the two groups. Most of the 
amino acids were located at the chain region and subunit interfaces, while four amino 
acids were located within the antigenic site (loop 160, amino acid number of B/HK/73) 
[51,52]. Additionally, four amino acids changed the charge property from group 1 to 
group 2 viruses (Table 5, No. 56, 116, 181 and 182, amino acid number of 
B/Yamagata/16/88). Different carbohydrate binding properties were also observed 
between some viruses of the two groups. Specifically, group 2 viruses interacted with 
three major sialylated glycans, while some of group 1 viruses bound not only strongly to 
the three glycans, but also weakly to sulfated and α2-3 sialylated glycans. Additionally, 
the number of charged amino acids was higher in group 2 than in group 1 viruses and 
B/HongKong/8/73 (Table 5). 
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Table 5. Critical amino acid differences between the two groups of influenza B clinical isolated viruses 
[50]. 
According to the binding preference for α2-6 and α2-3 sialylated oligosaccharides displayed 
by these clinical isolated influenza viruses, these clinical isolates might infect not only the 
surface of nasal mucosa, pharynx, larynx, trachea and bronchi (that are resided in the upper 
respiratory tract to express α2-6 sialosides predominantly), but also alveoli, bronchi (that are 
located in the lower respiratory tract), eyes, and tissues in the gastrointestinal tract (that 
contain both α2-3 and α2-6 sialosides) [53,54]. After we surveyed more clinical isolates, 
factors which affect the binding preference of IB could be dissected. We believe that 
application of the carbohydrate microarray for detailed analysis of sugar-binding structures 
will eventually build the connection between clinical symptoms and the genetic 
specification of influenza viruses. 
3.5. Characterization the glycan structure of glycoproteins (solution microarray) 
The aforementioned lectins are further applied to characterize the glycan structures of six 
biotinylated proteins including ovalbumin, porcine mucin, human serum albumin, human 
transferrin, fetuin and asialofetuin. Distinctive glycopatterns are generated in accordance 
with the analysis of lectins (Figure 9). Porcine mucin is known to have O-linked fucosylated 
glycans with terminal GalNAc, GlcNAc and NeuAc residues. Our results showed positive 
signals in the tests with the ECA, DBA, UEA-1 and WGA lectins, indicating that the mucin 
contains the determinants of Galβ1-4GlcNAc, GalNAc, Fucα1-2Gal and GlcNAc/NeuAc, 
respectively. Manα1-3(Fucα1-6)GlcNAc and NeuAcα2-6Galβ1-4GlcNAc containing 
biantennary or triantennary N-glycans have been reported as the major glyco-structures of 
human transferrin [55-58]. Strong Con A and SNA signals are shown in our binding assay, 
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but the relative intensity of GlcNAc-binding lectins is not as good as those of Con A and 
SNA, which is the contribution of the interference by the terminal sialic acids [59]. All of the 
results are similar to the analyses from lectin microarray or dot blot analysis [55-58]. 
 
Figure 9. Glycopattern profiling of six biotinylated proteins with ten lectins by glycan solution 
microarray. The six proteins include ovalbumin, porcine mucin, human serum albumin, human 
transferrin, fetuin and asialofetuin [28]. 
4. Perspective 
In summary, carbohydrate-protein interactions are the key steps for many physiological and 
pathological evens. Hence, development of new carbohydrate microarrays is important for 
detecting these activities. Our studies have demonstrated a rapid, highly sensitive, and 
reliable method to characterize carbohydrate-protein interactions with minimized materials 
(in the range of ng per well). Lectins and antibodies are evaluated and most of the results 
are coherent to previous reports, including those of CFG. Solution microarray is the first 
homogeneous and washless carbohydrate microarray which offers a reliable alternative for 
characterizing sugar-binding features of lectins and proteins, as well as antibodies. In 
addition, membrane microarray is also easy handled with low cost (USD$0.25 for one 
membrane microarray). The easy-handling feature avoids the necessity of repetitive training 
and accelerates the screening efficiency. Both of the microarrays represent a convenient and 
reliable way to examine the carbohydrate-binding features of various proteins, high-
throughput drug screening, and the glycan binding surveillance of influenza viruses. 
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